Appendix B

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Tocilizumab for the treatment of rheumatoid arthritis

Matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Roche Products (tocilizumab) Patient/carer groups • Arthritis & Musculoskeletal Alliance (ARMA) • Arthritis Care • National Rheumatoid Arthritis Society Professional groups • British Health Professionals in Rheumatology • British Society for Rheumatology • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians Others • Department of Health • Welsh Assembly Government	General • Department of Health, Social Services and Public Safety for Northern Ireland • NHS Quality Improvement Scotland Possible comparator manufacturer(s) • Abbott Laboratories (adalimumab) • AstraZeneca UK (chloroquine) • GlaxoSmith Kline (azathioprine) • Novartis (ciclosporin) • Pfizer (methotrexate, sulfasalazine, etanercept) • Roche Products (rituximab) • Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate) • Schering-Plough (infliximab) Relevant research groups • None Evidence Review Group • West Midlands Health Technology Assessment Collaboration • National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) Associated Guideline Groups • None Associated Public Health Groups • None

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists

Na
M
Is

contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.